Kenneth A. Orr

Kenneth A. Orr is the Founder and President of Triumph Small Cap Fund, Inc (TSC Fund), a venture capital firm in Melville, NY investing in emerging companies whose technology has the potential to dominate and or change an industry. Since 1997, Mr. Orr has been an early investor and/or financier of numerous public and private businesses. As a financier, Kenneth Orr has been credited with offering start-ups and small companies the financial resources to accomplish their goals and creating sustainable shareholder value through use of equity and debt based securities.

Prior to TSC Fund and shortly after graduating with a BS from Tufts University, Mr. Orr joined a small family business, North American Agriculture, Inc. (NAA), a global physical commodity trading company with warehousing and transportation operations. During Mr. Orr’s six years with NAA as head of commodity trading and head of M&A activities, the company’s workforce rose to over 320 employees and sales increased by 600%. After selling his interest in NAA, Mr. Orr founded the investment banking and brokerage firm, First Cambridge Securities, which served over 15,000 clients with offices in New York and Los Angeles. First Cambridge Securities employed over 350 employees in just three years since its inception.

Mr. Orr also serves on the board of numerous local and national charities, including serving on the board of the North Shore LIJ Hospital New Leadership Division, and is the founder of The Orr Foundation, which was established in 2004 for the purpose of funding educational programs, religious and racial appreciation, research for disease prevention and cures, as well as the fight against domestic violence. Mr. Orr was formerly the President of The Lawrenceville School Camp, which offers a summer camp program to inner city children. In addition, The Orr Foundation is a proud sponsor of the MPowering Kids program.

Steven M. Paul, MD

Steven M. Paul, MD, is the Director of the Helen and Robert Appel Alzheimer's Disease Research Institute and the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases. Dr. Paul is also a Professor of Neuroscience, Psychiatry and Pharmacology at Weill Cornell Medical College. He was formerly the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories (LRL) of Eli Lilly and Company. Prior to assuming his position at Lilly and Weill Cornell Medical College, Dr. Paul served as Scientific Director of the National Institute of Mental
Health (NIMH/NIH) in Bethesda, Maryland.

Dr. Paul is a member of various professional and honorary societies, including Phi Eta Sigma; Alpha Epsilon Delta; Sigma Xi; Phi Beta Kappa; and the Alpha Omega Alpha Honorary Medical Society. He is the recipient of many honors and scientific recognitions, including: The Distinguished Service Medal of the USPHS and the Chief Scientific Officer of the Year Award. In 1997, Dr. Paul was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences and currently serves on the IOM's Board on Health Sciences Policy. In 2009 Dr. Paul was elected a Fellow of the American Association for the Advancement of Science (AAAS).

Dr. Paul has authored or co-authored over 500 papers and invited book chapters and was listed as one of the most highly cited scientists in the world (top 50 in Neuroscience) (1980-2000) by the Institute for Scientific Information (I.S.I.), Philadelphia, Pennsylvania. He holds 9 patents on inventions made both at NIH and Lilly. His current work has focused on the role of apoE in the pathogenesis of Alzheimer's disease.
He is also an inventor of solanezumab, a humanized anti-Aß monoclonal antibody currently in late-stage clinical testing by Lilly as a potential disease-modifying treatment for Alzheimer's disease. Dr. Paul is on the boards of several publicly traded and private biopharmaceutical companies and is a founder of two start-up biotechnology companies dedicated to discovering and developing novel psychiatric drugs, including drugs for mood and psychotic disorders.

William Z. Potter, M.D., Ph.D., is recognized world-wide as an expert in the field of neuropsychopharrnacology and the development of novel drugs for major Central Nervous System (CNS) disorders. Most recently, he served as Vice President of Translational Neuroscience at Merck Research Laboratories, prior to which he was head of early CNS development at Lilly Research Laboratories (1996-2004).

Before working in the pharmaceutical industry, Dr. Potter had a distinguished career at the National Institutes of Health (NIH), where in 1971 he began as a fellow in the laboratory of B. B. Brodie. During his 25 year career in the Public Health Service, mainly in the National Institutes of Mental Health (NIMH), he authored over 200 publications, won Distinguished Service and Alumni Awards, and was a mentor to numerous current chairs of departments in academia across US, Europe, South America and China, as well as senior executives in industry.

Dr. Potter received his undergraduate, graduate (pharmacology), and medical degrees from the University of Indiana and is board certified in Psychiatry. He served as Senior Surgeon and Medical Director in the US Military (1971-1995).

Dr. Potter was one of the early architects of the Alzheimer Disease Neuroimaging Initiative (ADNI), and he continues as former chair and active participant on the Industry Strategic Advisory Board. For the past 18 months he has served as co-chair of the Foundation of the National Institute of Health Biomarkers Consortium Neuroscience Steering Committee, where he has championed the collaborative development of both biochemical and cognitive measures to enhance drug development of Alzheimer's and other brain diseases. In addition, he serves on the Institute of Medicine Forum on Neuroscience where he has organized and chaired public forums on such diverse topics as: suicidology and novel CNS biomarkers. As current Chair of the American College of Neuropsychopharmacology Goverument, Industry, Academia Liaison Committee, Dr. Potter focuses on opportunities to align and leverage efforts among stakeholders, and has recently been working with the leadership of both the Alzheimer's Association and National Alliance for the Mentally III as representatives of patient concerns.

Dr. Potter's current major interest is in seeing that everything possible is done to "realize the potential of methods that have been advanced over the last decade that allow one to better explore the physiological and biochemical processes associated with brain function, especially with regard to Alzheimer's and other neurodegenerative diseases.